Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.

Sunil PancholiMariana Ferreira LealRicardo RibasNikiana SimigdalaEugene SchusterSophie Chateau-JoubertLila ZabagloMargaret HillsAndrew DodsonQiong GaoStephen R JohnstonMitch DowsettSabina C CosulichElisabetta MaragoniLesley-Ann Martin

Published in: Breast cancer research : BCR (2019)

These data support the notion that models of acquired endocrine resistance may have a different sensitivity to mTOR inhibitor/endocrine therapy combinations.

Keyphrases

cell proliferation
electronic health record
big data
machine learning
young adults
metastatic breast cancer
bone marrow